Robert Arch
Plus aucun poste en cours
Fortune : - $ au 31/03/2024
Profil
Robert H.
Arch served as President, CEO & Non-Independent Director at OncoSec Medical, Inc. from 2022 to 2023.
Prior to that, he was Head-Research at Elpiscience Biopharma Ltd.
from 2019 to 2021 and Head-Liver Disease Department at China Novartis Institutes for BioMedical Research Co., Ltd.
from 2017 to 2019.
Arch holds a doctorate degree from Julius-Maximilians-Universität Würzburg.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
21/03/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Anciens postes connus de Robert Arch
Sociétés | Poste | Fin |
---|---|---|
ONCOSEC MEDICAL INCORPORATED | Chief Executive Officer | 14/06/2023 |
Elpiscience Biopharma Ltd.
Elpiscience Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Elpiscience Biopharma Ltd. engages in the development of cutting-edge immunotherapies to fight cancer. Its business scope includes technology research and development, transfer of own technology achievements and provision of related technical advice and technical services of biomedicine and biotechnology; import and export, and wholesale of mechanical equipment, electronic products, instrumentation, and plastic products. The company was founded on September 30, 2017 and is headquartered in Shanghai, China. | Chief Tech/Sci/R&D Officer | 01/06/2021 |
China Novartis Institutes for BioMedical Research Co., Ltd. | Corporate Officer/Principal | 01/10/2019 |
Formation de Robert Arch
Julius-Maximilians-Universität Würzburg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
ONCOSEC MEDICAL INCORPORATED | Health Services |
Entreprise privées | 2 |
---|---|
Elpiscience Biopharma Ltd.
Elpiscience Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Elpiscience Biopharma Ltd. engages in the development of cutting-edge immunotherapies to fight cancer. Its business scope includes technology research and development, transfer of own technology achievements and provision of related technical advice and technical services of biomedicine and biotechnology; import and export, and wholesale of mechanical equipment, electronic products, instrumentation, and plastic products. The company was founded on September 30, 2017 and is headquartered in Shanghai, China. | Health Technology |
China Novartis Institutes for BioMedical Research Co., Ltd. |